CRKL and hepatocellular carcinoma: Additionally, miR-429 was suggested as a tumor suppressor in hepatocellular carcinoma by targeting CRKL via inhibiting the Raf/MEK/ERK pathway and the epithelial-mesenchymal transition, which leads to a decrease in tumor migration and invasion [44].